We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Elevated Protein Biomarker Predict Brain Injury in Newborns

By LabMedica International staff writers
Posted on 02 Nov 2011
Increased blood levels of a protein specific to central nervous system cells help physicians identify newborns with brain injuries due to lack of oxygen.

Measurements of the protein that are vital to the brain’s structure can also track how well a body-cooling therapy designed to prevent permanent brain damage is working.

Scientists at the Johns Hopkins Children's Center (Baltimore, MD, USA) studied the levels of glial fibrillary acidic protein (GFAP) in 23 newborns born between 36 and 41 weeks’ gestation who were diagnosed with clinical oxygen deficiency to the brain (hypoxic-ischemic encephalopathy, or HIE). More...
They compared these levels with those from babies born at the same point in the pregnancy without brain injury.

The investigators developed an electrochemiluminescent sandwich immunoassay for GFAP using the Mesoscale platform (MesoScale Discovery; Gaithersburg, MD, USA). This method uses a trio of mouse monoclonal antibodies for capture and a rabbit polyclonal for detection. The lower limit of quantitation was 0.04 ng/mL; values below this were reported as zero.

As part of the study, the scientists obtained the GFAP protein from cord blood at the time of birth, from neonatal blood drawn upon admission to the neonatal intensive care unit (NICU) and from daily blood specimens over a seven-day period. GFAP levels were significantly higher in babies with brain injury due to a lack of oxygen during the first week of life. Infants in the study, who had abnormal brain MRI scans and treated with whole-body cooling, had the highest levels of GFAP. The treatment lowers body temperature to 33.5 °C, beginning within six hours of birth and continuing for three days. Half of the babies with brain injury in this study had increased levels of GFAP after completion of the 72-hour cooling period.

Ernest M. Graham, MD, a maternal-fetal medicine expert at Johns Hopkins, noted that GFAP, a circulating brain-specific protein, is already measured in adult patients after stroke, cardiac arrest, or traumatic brain injury in an effort to provide a prognosis for survival or brain damage. He added, “Now we know this biomarker can serve as a valid predictor of disease, injury evolution, and outcome in newborns." The authors concluded that GFAP could be used to more specifically and sensitively diagnose brain injury at birth. This could facilitate triage of infants into HIE treatment protocols with hypothermia plus adjuvant treatments, serve as an intermediate outcome to benchmark evolving HIE therapies, and give prognostic information to the parents of these at risk children.

The study was published September 2011, in the American Journal of Obstetrics and Gynecology .

Related Links:
Johns Hopkins Children's Center
MesoScale Discovery




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.